Hospital

Results demonstrating safety and efficacy in those with anemia in non-dialysis dependent chronic kidney disease and anemia in dialysis-dependent chronic kidney disease were presented at the 2024 American Society of Nephrology Kidney Week.

Zaltenibart could be an effective treatment option for C3 glomerulopathy as the most proximal inhibitor of the alternative pathway.

NCCN recommends ribociclib as a preferred CDK4/6 inhibitor adjuvant therapy for patients with HR+/HER2- EBC in combination with an aromatase inhibitor.

Utilizing data from the CHAMPION MG trial, investigators found that many patients had responded to ravulizumab and returned to daily activities within 2 weeks.

Historically, colchicine has been used primarily in the management of gout; however, in 2023, the FDA approved Lodoco, a newly marketed colchicine product, for the management of cardiovascular disease.

Congenital muscular dystrophy type 1a is a severe, early-onset condition that currently has no treatment, but MDL-101 may serve as a 1-time, durable treatment option.

Sara Rogers, PharmD, discusses the formation and goals of the Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) initiative, which seeks to standardize pharmacogenomic practices and improve clinical decision-making by establishing consensus across all stakeholders.

Findings highlight the need for health care providers to continue to educate patients on the risk of scurvy, ensuring proper vitamin C intake.

Pharmacists are encouraged to leverage prescription drug monitoring programs connect patients to community-based resources to address the opioid crisis and pharmacy deserts.

Damage to a Baxter manufacturing plant in the aftermath of Hurricane Helene has led to significant IV fluid shortages throughout the country.

Treatment with valacyclovir for a year decreased the risk of new or worsening eye disease by 26%.

Despite self-reported improvements in cognitive function, neuropsychological tests showed little differences between 2 patient groups.

Benjamin Brown of Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) discusses his own experience as a patient with cancer and how consensus around pharmacogenomic practices can improve the lives of patients.

The approval marks Abrysvo as the first and only RSV vaccine designated for adults younger than 50 that are at increased risk for LRTD.

Benefits include reducing serious health consequences, such as hospitalization and death, as well as the economic burden on health systems due to influenza infection.

Higher doses of β-blockers are associated with better clinical outcomes in patient with heart failure.

Pharmacists will likely be the first contact for many affected patients, and they should be able to provide evidence-based advice on how to manage their infection.

Despite suggestions to the contrary in previously conducted small clinical trials, montelukast did not provide benefit in patients with COVID-19 symptoms.

Ginger Blackmon, PharmD, will discuss enhancing patient cancer care through implementation of medically integrated oncology team and NCODA’s PQI resources.

Endometriosis is a systemic disease that can affect multiple parts of the body, not just the pelvis.

New recommendations from the American Stroke Association (ASA) emphasize the importance of healthy lifestyle habits and addressing health equity to reduce stroke risk.

Pharmacists are positioned to combat the opioid crisis through educating the public and advocating for policy changes to enable harm reduction strategies.

In April 2024, the FDA approved ustekinumab-aekn as a subcutaneous injection for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis.

There are gonadotoxic risks of chemotherapy, radiation, and surgery that are important to discuss with patients.

Multiple P13K inhibitors have showed promise in treating genetically-mutated forms of breast cancer.

Therapy-related complications, in addition to financial obstacles, can complicate myasthenia gravis treatment.

The implementation of accountable care organizations (ACOs) also worsened disparities in any emergency department or hospital use for Medicaid-insured children with asthma.

The study was conducted on a small subgroup of Japanese patients with myelofibrosis.